Head-to-head evidence
Belantamab mafodotin vs IM21 CAR-T cells
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Belantamab mafodotin
Marketed by GlaxoSmithKline
NCT03525678 · Phase 2 · completed
This was a randomized but open-label phase 2 study in which all participants received belantamab mafodotin at one of two doses or formulations; there was no placebo or active comparator arm and no blinding. The primary endpoint was overall response rate by independent review, a clinical response measure, but the results are reported as per-arm rates with confidence intervals and no formal statistical comparison against a control, so the study cannot distinguish drug effect from natural history or placebo effect. The evidence is therefore descriptive phase 2 evidence of activity, not strong comparative evidence.
Next expected readout: October 2026 · NCT05573802 (registry estimate)
IM21 CAR-T cells
Developed by Beijing Immunochina Medical Science & Technology Co., Ltd.
NCT03711864 · Phase 1 · status unknown
This is a small, unblinded, single-arm safety study with no comparison group, and no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Belantamab mafodotin's landscape · IM21 CAR-T cells's landscape